Ionis Pharmaceuticals (Nasdaq: IONS) and AstraZeneca announced today that their Phase 3 CARDIO-TTRansform trial for eplontersen failed its primary endpoint. The study evaluated eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Results showed no statistically significant benefit in the composite outcome of cardiovascular mortality and recurrent cardiovascular events versus placebo.
The failure marks a significant setback for Ionis, as eplontersen targeted a large and competitive market. The companies noted that adding eplontersen provided no significant benefit over current standard-of-care stabilizer therapies. This outcome raises questions regarding the drug's viability for this specific patient population.
The negative results will likely impact Ionis stock and reshape the competitive landscape for ATTR-CM treatments. The drug remained well-tolerated, but the lack of efficacy stalls expansion into the lucrative cardiomyopathy market. Investors in the cardiovascular and rare disease sectors closely monitor this indication.